353 related articles for article (PubMed ID: 19005469)
41. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.
Liu Y; el-Ashry D; Chen D; Ding IY; Kern FG
Breast Cancer Res Treat; 1995 May; 34(2):97-117. PubMed ID: 7647336
[TBL] [Abstract][Full Text] [Related]
42. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer.
Stål O; Borg A; Fernö M; Källström AC; Malmström P; Nordenskjöld B;
Ann Oncol; 2000 Dec; 11(12):1545-50. PubMed ID: 11205461
[TBL] [Abstract][Full Text] [Related]
43. Functional genomic methods to study estrogen receptor activity.
Gilfillan S; Fiorito E; Hurtado A
J Mammary Gland Biol Neoplasia; 2012 Jun; 17(2):147-53. PubMed ID: 22588661
[TBL] [Abstract][Full Text] [Related]
44. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer.
Murphy LC; Leygue E; Niu Y; Snell L; Ho SM; Watson PH
Br J Cancer; 2002 Dec; 87(12):1411-6. PubMed ID: 12454770
[TBL] [Abstract][Full Text] [Related]
45. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
46. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
47. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M; Dowhan DH
Neoplasia; 2012 Apr; 14(4):283-96. PubMed ID: 22577344
[TBL] [Abstract][Full Text] [Related]
48. PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype.
Beauchemin D; Lacombe C; Van Themsche C
Mol Cancer; 2011 Dec; 10():148. PubMed ID: 22168360
[TBL] [Abstract][Full Text] [Related]
49. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
[TBL] [Abstract][Full Text] [Related]
50. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
Sharma D; Saxena NK; Davidson NE; Vertino PM
Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
[TBL] [Abstract][Full Text] [Related]
51. Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.
Moi LL; Flågeng MH; Gjerde J; Madsen A; Røst TH; Gudbrandsen OA; Lien EA; Mellgren G
BMC Cancer; 2012 Jun; 12():247. PubMed ID: 22703232
[TBL] [Abstract][Full Text] [Related]
52. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis.
Wu H; Chen Y; Liang J; Shi B; Wu G; Zhang Y; Wang D; Li R; Yi X; Zhang H; Sun L; Shang Y
Nature; 2005 Dec; 438(7070):981-7. PubMed ID: 16355216
[TBL] [Abstract][Full Text] [Related]
53. Is tamoxifen the Rosetta stone for breast cancer?
Jordan VC
J Natl Cancer Inst; 2003 Mar; 95(5):338-40. PubMed ID: 12618491
[No Abstract] [Full Text] [Related]
54. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
[TBL] [Abstract][Full Text] [Related]
55. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.
Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Buggy Y; Young LS
Clin Cancer Res; 2005 Mar; 11(6):2111-22. PubMed ID: 15788656
[TBL] [Abstract][Full Text] [Related]
56. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
57. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
58. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.
Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Rydén S; Sigurdsson H
Cancer Lett; 1994 Jun; 81(2):137-44. PubMed ID: 7912163
[TBL] [Abstract][Full Text] [Related]
59. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
60. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M
J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
